Elliot B Tapper1,2. 1. Division of Gastroenterology and Hepatology, University of Michigan, Ann Arbor, MI. 2. Gastroenterology Section, VA Ann Arbor Healthcare System, Ann Arbor, MI.
Abstract
Hepatic encephalopathy (HE) is associated with poor quality of life, sharply increased mortality, repeated hospitalizations, falls, and motor vehicle accidents. HE manifests with a dynamic spectrum of severity. Overt HE is clinically obvious disorientation, even coma. Although multiple strategies are available to characterize early-stage HE, data are limited that validate these methods in predicting overt HE, many are impractical in clinical practice, and test cutoffs relevant to the average patient clinicians manage are lacking. To accurately and efficiently classify the risk of overt HE in the population with cirrhosis, novel strategies may be needed. Herein, we review the potential competing strategies for the prediction of overt HE. Conclusion: We propose refining diagnostic cutoffs for tests that are designed to define early HE, using overt HE as a gold standard and expanding prediction tools by using measures of components from the risk pathway for HE.
Hepatic encephalopathy (HE) is associated with poor quality of life, sharply increased mortality, repeated hospitalizations, falls, and motor vehicle accidents. HE manifests with a dynamic spectrum of severity. Overt HE is clinically obvious disorientation, even coma. Although multiple strategies are available to characterize early-stage HE, data are limited that validate these methods in predicting overt HE, many are impractical in clinical practice, and test cutoffs relevant to the average patient clinicians manage are lacking. To accurately and efficiently classify the risk of overt HE in the population with cirrhosis, novel strategies may be needed. Herein, we review the potential competing strategies for the prediction of overt HE. Conclusion: We propose refining diagnostic cutoffs for tests that are designed to define early HE, using overt HE as a gold standard and expanding prediction tools by using measures of components from the risk pathway for HE.
Authors: P Amodio; A Pellegrini; E Ubiali; I Mathy; F Del Piccolo; R Orsato; A Gatta; J M Guerit Journal: Clin Neurophysiol Date: 2006-08-22 Impact factor: 3.708
Authors: Manuel Romero-Gómez; María Jover; José A Del Campo; José L Royo; Elena Hoyas; José J Galán; Carmina Montoliu; Eugenia Baccaro; Mónica Guevara; Juan Córdoba; Germán Soriano; José M Navarro; Carmen Martínez-Sierra; Lourdes Grande; Antonio Galindo; Emilia Mira; Santos Mañes; Agustín Ruiz Journal: Ann Intern Med Date: 2010-09-07 Impact factor: 25.391
Authors: Carmina Montoliu; Blanca Piedrafita; Miguel A Serra; Juan A del Olmo; Amparo Urios; Jose M Rodrigo; Vicente Felipo Journal: J Clin Gastroenterol Date: 2009-03 Impact factor: 3.062
Authors: Jasmohan S Bajaj; Kia Saeian; Christine M Schubert; Muhammad Hafeezullah; Jose Franco; Rajiv R Varma; Douglas P Gibson; Raymond G Hoffmann; R Todd Stravitz; Douglas M Heuman; Richard K Sterling; Mitchell Shiffman; Allyne Topaz; Sherry Boyett; Debulon Bell; Arun J Sanyal Journal: Hepatology Date: 2009-10 Impact factor: 17.425
Authors: Elliot B Tapper; Lilli Zhao; Samantha Nikirk; Jad Baki; Neehar D Parikh; Anna S Lok; Akbar K Waljee Journal: Am J Gastroenterol Date: 2020-12 Impact factor: 12.045
Authors: Charlotte W Wernberg; Ove B Schaffalitzky de Muckadell; Hendrik Vilstrup; Mette M Lauridsen Journal: PLoS One Date: 2019-12-12 Impact factor: 3.240